INNOVATION IN ONCOLOGY: new drugs and the impact of artificial intelligence
INNOVATION IN ONCOLOGY: new drugs and the impact of artificial intelligence
The FGB-FM-ESO Joint International Conference 2025 brings together world-leading experts in oncology to explore cutting-edge developments in cancer therapeutics and the transformative potential of artificial intelligence in clinical practice. This two-day conference will foster collaboration between clinicians and researchers, promoting knowledge exchange and innovation in cancer care. Besides, the conference hosts the “Gianni Bonadonna Prize” for young investigators in the field of innovative therapies in oncology. This year is the 10th Anniversary since the passing of Gianni Bonadonna, and this award will be an important occasion to honour one of the founding fathers of modern oncology.
Conference Aims:
- To showcase breakthrough developments in cancer therapeutics, with a focus on novel drug delivery systems and targeted therapies
- To explore the integration of artificial intelligence in oncology, from diagnosis to treatment selection
- To facilitate knowledge transfer between academic research and clinical practice
- To promote collaboration between established researchers and emerging talent in the field
- To provide a platform for discussing practical implementation challenges and solutions
OFFICIAL LANGUAGE
The official language will be English. No translation will be available.VENUE
The Convention will be held at Fondazione Prada, Godard Cinema, Largo Isarco 2 - Milan, ItalyCME ACCREDITATION
The conference has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for 8.5 European CME credits (ECMEC®s).PARTICIPATION
Attendance is limited to 180 participants and admittance is on a first come, first served basis.The registration grants you:
- Free registration
- Meals according to the programme
It does not cover travel costs, accommodation and extra expenses, these should be organized and paid by the participant. Accompanying persons will not be accepted.
INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation in the event. Participants are advised to take out their own personal and travel insurance coverage.ORGANISING SECRETARIAT
Sonia Bulgarelli
European School of Oncology
m: +39 3371061207
Alice Ciocchini
European School of Oncology
m: +39 3371061207
Registration and networking
Welcome and introduction
SESSION 1: EMERGING PARADIGMS IN DRUG DEVELOPMENT
Next-Generation Antibody-Drug Conjugates: Design Principles and Clinical Applications
Raffaele Colombo (CA)Emerging Paradigms in Cancer Immunotherapy
Giampaolo Bianchini (IT)New Frontiers in Endocrine Therapy for Breast Cancer
Rinath Jeselsohn (US)T Cell Engineering for Solid Tumors: Challenges and Opportunities
Chiara Bonini (IT)Discussion
GIANNI BONADONNA PRIZE 2025: THE AWARD CEREMONY
Presentation of the winner project
SESSION 2: DIAGNOSTIC REVOLUTION IN ONCOLOGY AND ROLE OF ARTIFICIAL INTELLIGENCE
Clinical utility of ctDNA for treatment monitoring and early detection of resistance mechanisms in metastatic breast cancer
Isaac Garcia-murillas (UK)Radiomics: Transforming Imaging Data into Precision Oncology
Irène Buvat (FR)Utilizing Computational Pathology to Discover Biomarkers for Predicting Response in breast and ovarian cancer
Sara Pires De Oliveira (NL)Breakthrough technologies: single-cell and spatially resolved
Lubna Ahmad (UK)Coffee Break
Biomarker development and clinical application: breast cancer as a model
Lajos Pusztai (US)From cloud to bedside: Responsible AI predictive models in healthcare
Carlo Tacchetti (IT)Critical view of AI in Oncology
Ian Tannock (CA)Discussion
Lunch
SESSION 3: NEW HORIZONS IN ONCOLOGY DRUG DEVELOPMENT
Revolutionizing Dose Optimization, Efficacy Evaluation, and Tumor-Agnostic Methods in Early-Phase Clinical Trials
Vivek Subbiah (US)Post-Approval Dose Optimization to Improve the Therapeutic Index and Reduce Costs
Mark J. Ratain (US)Tumor adaptive responses and rational development of drug combinations
Diego Tosi (FR)Discussion
Conclusions
Carlo Tacchetti
IRCCS Ospedale San Raffaele, IRCCS Ospedale San Raffaele, Milano, IT
Chiara Bonini
IRCCS Ospedale San Raffaele, Experimental hematology, Milano, IT
Diego Tosi
Cancer Institute of Montpellier (ICM), Oncology, Montpellier, FR
Giampaolo Bianchini
Ospedale San Raffaele, Dept. of Medical Oncology - O.U. Medicine 1Q-A, Milano, IT
Ian Tannock
Princess Margaret Cancer Centre & University of Toronto, Toronto, CA
Irène Buvat
Institut Curie Paris, Director Laboratory of Translational Imaging in Oncology, Paris, FR
Isaac Garcia-murillas
The Institute of Cancer Research, Molecular Oncology, London, UK
Lajos Pusztai
Yale Cancer Center, Scientific Co-Director of the Center for Breast Cancer, New Haven, US
Lubna Ahmad
CRUK, Cancer Research UK Cambridge Centre, Cambridge, UK
Mark J. Ratain
Cancer Research Center, The University of Chicago, Dept. of Medicine, Chicago, US
Raffaele Colombo
Zymeworks Inc, ADC Therapeutic Development, Vancouver, CA
Rinath Jeselsohn
Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Boston, US
Sara Pires De Oliveira
Netherland Cancer Institute, Amsterdam, Netherlands, ., Amsterdam, NL
Vivek Subbiah
Sarah Cannon Research Institute (SCRI), Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, US
Attendance is limited to 180 participants and admittance is on a first come, first served basis.
HOW TO REGISTER
Interested PARTICIPANTS should register online (at the top of this page).
Once registered, participants will receive a confirmation email with details
